The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland
Authors' conclusion
Prior antiresorptive therapy blunted the BMD response to romosozumab, and the duration was correlated with BMD changes at both the lumbar spine and total hip.
Study context
- Population
- High-risk osteoporosis patients receiving romosozumab in a nationwide Swiss osteoporosis registry (92 women, 7 men; median age 71 years [65, 76]), enrolled January 2021 to December 202392 women and 7 men
- Participants
- 99 patients
- Exposure
- Romosozumab for 12 months in pre-treated vs treatment-naïve patients
- Pre-treatedn = 77
- Treatment naïven = 22reference
- Outcome
- BMD change on romosozumab, taking into account prior therapies
- Follow-up
- 12 months
Methodological detailsmulticentre, nationwide Swiss osteoporosis registry
- Multicentre
- Nationwide Swiss osteoporosis registry
Main finding
As reported in the abstract
BMD change on romosozumab, all patients
Lumbar spine bone mineral density (BMD) change
10.3%
7.5, 15.5
Total hip BMD change
3.1%
1.1, 5.8
Femoral neck BMD change
3.1%
0.5, 5.3
Observational data: associations, not effects.
Further findings
Other predictors of BMD change
- Total hip: baseline hip T-scores, BMI and baseline CTX
- Lumbar spine: baseline lumbar spine T-score, age and baseline CTX
Original publication
The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int. Published 26 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →